Clinical observation of three dimensional conformal radiotherapy with tamoxifen in treatment of postoperative malignant glioma

Asian Pac J Cancer Prev. 2015;16(5):1743-5. doi: 10.7314/apjcp.2015.16.5.1743.

Abstract

Objective: To evaluate the efficacy and adverse effects of three dimensional conformal radiotherapy (3D-CRT) with tamoxifen in treating patients with postoperative malignant glioma.

Patients and methods: 60 patients of postoperative malignant glioma were randomly assigned into two groups, 30 patients were treated with 3D-CRT plus tamoxifen (treatment group), and the other 30 patients with 3D-CRT plus temozolomide (control group). All patients were radiated by 6MV X-ray, 2.0 Gy per fraction, once daily, with a total dose (DT) of 56~60 Gy. Tamoxifen was delivered at 60 mg /m2/d, temozolomide was given at 75 mg/m2/d. All patients were treated with concurrent radiotherapy.

Results: One, 2, 3 year survival rates of treatment and control group were 63.3%, 30.0%, 23.0% and 70.0%, 33.3%, 26.7%, respectively (χ2=0.01, 0.23, 0.09, P>0.05). The rate of thromboembolism in treatment group was 6.7%.

Conclusion: Therapeutic efficacy of two groups was similar, but it was more cost- effective in treatment group, and toxicity did not increase.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Combined Modality Therapy / adverse effects
  • Combined Modality Therapy / economics
  • Combined Modality Therapy / methods*
  • Dacarbazine / analogs & derivatives*
  • Dacarbazine / economics
  • Dacarbazine / therapeutic use
  • Disease-Free Survival
  • Female
  • Glioma / therapy*
  • Humans
  • Male
  • Middle Aged
  • Postoperative Period
  • Radiotherapy, Conformal / methods*
  • Random Allocation
  • Survival Rate
  • Tamoxifen / economics
  • Tamoxifen / therapeutic use*
  • Temozolomide
  • Thromboembolism / epidemiology
  • Treatment Outcome
  • Young Adult

Substances

  • Antineoplastic Agents, Alkylating
  • Antineoplastic Agents, Hormonal
  • Tamoxifen
  • Dacarbazine
  • Temozolomide